AT845 Gene Therapy Trial to Restart Now That FDA Has Lifted Hold
FORTIS, a Phase 1/2 clinical trial of an experimental gene therapy called AT845, is due to restart in adults with late-onset Pompe disease (LOPD), thanks to a decision by the U.S. Food and Drug Administration (FDA). The trial was put on hold mid-2022 after one of its…